1. Lin TE, Chou CH, Wu YW, Sung TY, Hsu JY, Yen SC, Hsieh JH, Chang YW, Pan SL, Huang WJ, Hsu KC, Yang CR*. Identification of a potent CDK8 inhibitor using structure-based virtual screening. Journal of Chemical Information and Modeling. 2024; Accepted (SCI)

2. Chou CH, Huang WJ, Hsu KC, Hsu JY, Lin TE, Yang CR*. The cyclin-dependent kinase 8 inhibitor E966–0530–45418 attenuates pulmonary fibrosis in vitro and in vivo. International Journal of Biological Sciences. 2025; 21(2):685-707 (SCI)

3. Lin TE, Yen D, HuangFu WC, Wu YW, Hsu JY, Yen SC, Sung TY, Hsieh JH, Pan SL, Yang CR, Huang WJ, Hsu KC. An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors. Protein Science, 2024; 33(6):e5007 (SCI)

4. Tsai FL, Huang HL, Lai MJ, Liou JP, Pan SL, Yang CR*. Anticancer study of a novel pan-HDAC inhibitor MPT0G236 in colorectal cancer cells. International Journal of Molecular Sciences, 2023; 24(16):12588 (SCI)

5. Ho TY, Sung TY, Pan SL, Huang WJ, Hsu KC, Hsu JY, Lin TE, Hsu CM, Yang CR*. The study of a novel CDK8 inhibitor E966-0530-45418 that inhibits prostate cancer metastasis in vitro and in vivo. Biomedicine & Pharmacotherapy, 2023; 162:114667 (SCI)

6. Hsu JY, Hsu KC, Sun C, Chou CH, Lin TE, Sung TY, Tseng HJ, Yen SC, Yang CR*, Huang WJ*. Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors. Biomedicine & Pharmacotherapy, 2023; 159:114258 (SCI)

7. Zhang NY, Wang TH, Chou CH, Wu KC, Yang CR, Kung FL, Lin CH. Ibuprofen treatment ameliorates memory deficits in rats with collagen-induced arthritis by normalizing aberrant MAPK/NF-kB and glutamatergic pathways. European Journal of Pharmacology, 2022; 933:1752556 (SCI)

8. Yen SC, Wu YW, Huang CC, Chao MW, Tu HJ, Chen LC, Lin TE, Sung YT, Tseng HJ, Chu JC, Huang WJ, Yang CR, HuangFu WC, Pan SL, Hsu KC. O-methylated lavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia. Phytomedicine, 2022; 100:154061 (SCI)

9. Lin TE, Sung LC, Chao MW, Li M, Zheng JH, Sung TY, Hsieh JH, Yang CR, Lee HY, Cho EC, Hsu KC. Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022; 37(1):226-235 (SCI)

10. Lin TE, Chao MW, HuangFu WC, Tu HJ, Peng ZX, Su CJ, Sung TY, Hsieh JH, Lee CC, Yang CR, Pan SL, Hsu KC. Identification and analysis of a selective DYRK1A inhibitor. Biomedicine & Pharmacotherapy, 2022; 146:112580 (SCI)

11. Lin TE, Yang CR, Chou CH, Hsu JY, Chao MW, Sung TY, Hsieh JH, Huang WJ, Hsu KC. Discovery of a novel cyclin dependent 8 inhibitor with an oxindole core for anti-inflammatory treatment. Biomedicine & Pharmacotherapy. 2022; 146:112459 (SCI)

12. Chou CH, Yang CR*. Neuroprotective studies of evodiamine in an okadaic acid-induced neurotoxicity. International Journal of Molecular Sciences. 2021; 22(10):5347 (SCI)

13. Wu YW, Chao MW, Tu HJ, Chen LC, Hsu KC, Liou JP, Yang CR, Yen SC, HuangFu WC, Pan SL. A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo. Oncogenesis. 2021; 10(5):39 (SCI)

14. Chao MW, Lin TE, HuangFu WC, Chang CD, Tu HJ, Chen LC, Yen SC, Sung TY, Huang WJ, Yang CR, Pan SL, Hsu KC. Identification of a dual TAOK1 and MAP4K5 inhibitor using a structure-based virtual screening approach. Journal of Enzyme Inhibition and Medicinal Chemistry. 2021; 36(1): 98–108 (SCI)

15. Chou CH, Hsu KC, Lin TE, Yang CR*. Anti-inflammatory and tau phosphorylation-inhibitory effects of eupatin. Molecules. 2020; 25(23):5652 (SCI)

16. Jagtap AD, Kondekar NB, Hung PY, Hsieh CE, Yang CR, Chen GS, Chern JW. 4-Substituted 2-amino-3,4-dihydroquinazolines With a 3-hairpin Turn Side Chain as Novel Inhibitors of BACE-1. Bioorganic Chemistry. 2020; 95:103135 (SCI)

17. Huang JM, Huang FI, Yang CR*. Moscatilin ameliorates tau phosphorylation and cognitive deficits in Alzheimer’s disease models. Journal of Natural Products. 2019; 82(7):1979-1988 (SCI)

18. Huang FI, Wu YW, Sung TY, Liou JP, Lin MH, Pan SL, Yang CR*. MPT0G413, a novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells. Frontiers in Oncology. 2019; 9:249 (SCI)

19. Hsieh YL, Tu HJ, Pan SL, Liou JP, Yang CR*. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochimica et Biophysica Acta. Molecular Cell Research. 2019; 1866(6):992-1003 (SCI)

20. Tu HJ, Lin YJ, Chao MW, Sung TY, Wu YW, Chen YY, Lin MH, Liou JP, Pan SL and Yang CR*. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. Clinical Epigenetics. 2018; 10(1):162 (SCI)

21. Lee HY, Fan SJ, Huang FI, Chao HY, Hsu KC, Lin TE, Yeh TK, Lai MJ, Li YH, Huang HL, Yang CR*, Liou JP*.5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer’s Disease Phenotypes. Journal of Medicinal Chemistry. 2018; 61(16):7087-7102 (SCI)

22. Fan SJ, Huang FI, Liou JP, Yang CR*. The novel histone deacetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. Cell Death & Disease. 2018; 9:655 (SCI)

23. Lee HY, Nepali K, Huang FI, Chang CY, Lai MJ, Li YH, Huang HL, Yang CR*, Liou JP*. (N-Hydroxycarbonylbenylamino)quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in vitro and in vivo. Journal of Medicinal Chemistry. 2018; 61(3):905-917 (SCI)

24. Chao MW, Huang HL, HuangFu WC, Hsu KC, Liu YM, Wu YW, Lin CF, Chen YL, Lai MJ, Lee HY, Liou JP, Teng CM, Yang CR*. An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells. Oncotarget. 2017; 8(17):27772-27785 (SCI)

25. HuangFu WC, Chao MW, Cheng CC, Wei YC, Wu YW, Liou JP, Hsiao G, Lee YC, Yang CR*. Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo. Scientific Reports. 2017; 7:42291 (SCI)

26. Lee HY, Lee JF, Kumar S, Wu YW, HuangFu WC, Lai MJ, Li YH, Huang HL, Kuo FC, Hsiao CJ, Cheng CC, Yang CR*, Liou JP*. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity. European Journal of Medicinal Chemistry 2017; 125:1268-1278 (SCI)

27. Lee HY, Chang CY, Su CJ, Huang HL, Mehndiratta S, Chao YH, Hsu CM, Kumar S, Sung TY, Huang YZ, Li YH, Yang CR*, Liou JP*. 2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase. European Journal of Medicinal Chemistry 2016; 122:92-101 (SCI)

28. Chen MC, Huang HH,Lai CY, Lin YJ, Liou JP, Lai MJ, Li YH, Teng CM, Yang CR*. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget 2016; 7(1):402-417 (SCI)

29. Huang YC, Huang FI, Mehndiratta S, Lai SC, Liou JP, Yang CR*. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis. Oncotarget 2015; 6(21):18590-18601 (SCI)

30. Yang CR, Shih KS, Liou JP, Wu YW, Hsieh IN, Lee HY, Lin TC, Wang JH*. Denbinobin upregulates miR-146a expression and attenuates IL-1β-induced upregulation of ICAM-1 and VCAM-1 expression in osteoarthritis fibroblast-like synoviocytes. Journal of Molecular Medicine 2014; 92:1147-1158(SCI)

31. Hsieh IN, Liou JP, Lee HY, Lai MJ, Li YH and Yang CR*. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death & Disease 2014; 5:e1166(SCI)

32. Mehndiratta S, Hsieh YL, Liu YM, Wang AW, Lee HY, Kumar S, Teng CM, Yang CR*, Liou JP*. Indole-3-ethylsulfamoylphenylacrylamides: Potent Histone Deacetylase Inhibitors with Anti-inflammatory Activity. European Journal of Medicinal Chemistry 2014; 85:468-479(SCI)

33. Lee HY, Yang CR, Lai MJ, Huang HL, Hsieh YL, Liu YM, Yeh TK, Li YH, Mehndiratta S, Teng CM, Liou JP. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)indolines Histone Deacetylase Inhibitors Are Potent Cytokine Release Suppressors. ChemBioChem 2013; 14:1500-1504(SCI)

34. JH Wang, KS Shih, YW Wu, AW Wang, and CR Yang*. Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1beta signaling in osteoarthritis fibroblast-like synoviocytes. Osteoarthritis and Cartilage 2013; 21:1987-1996(SCI)

35. Wang JH, Shih KS, Liou JP, Wu YW, Chang ASY, Wang KL, Tsai CL, Yang CR*. Anti-arthritic effects of magnolol in human interleukin 1beta-stimulated fibroblast-like synoviocytes and in a rat arthritis model. PLoS ONE 2012; 7(2):e31368(SCI)

36. Shih KS, Wang JH, Wu YW, Teng CM, Chen CC, and Yang CR*. Aciculatin inhibits granulocyte colony-stimulating factor production by human interleukin 1β-stimulated fibroblast-like synoviocytes. PLoS ONE 2012; 7(7):e42389(SCI)

37. Chen PH, Peng CY, Pai HC, Teng CM, Chen CC, Yang CR*. Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways. Journal of Nutritional Biochemistry 2011; 22(8):732-740(SCI)

38. Liu HE, Chang ASY, Teng CM, Chen CC, Tsai AC, and Yang CR*. Potent anti-inflammatory effects of denbinobin mediated by dual inhibition of expression of inducible NO synthase and cyclooxygenase-2. Shock 2011; 35(2):191-197(SCI)

39. I-Ni Hsieh, Anita Shin-Yuan Chang, Che-Ming Teng, Chien-Chih Chen, and Chia-Ron Yang*. Aciculatin inhibits lipopolysaccharide-mediated inducible nitric oxide synthase and cyclooxygenase-2 expression via suppressing NF-kappaB and JNK/p38 MAPK activation pathways. The Journal of Biomedical Science 2011; 18(1):28(SCI)

40. Yang CR*, Lai CC. Thiazolidinediones inhibit TNF-alpha-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATc1. Shock 2010; 33(6):662-667(SCI)

41. Yang CR, Yu RK. Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. J Neurosci Res 2009; 87(1):26-33(SCI)

42. Yang CR*, Guh JH, Teng CM, Chen CC, Chen PH. Combined treatment with Denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells. Br J Pharmacol 2009; 157:1175-1185(SCI)

43. Chen PH, Yang CR*. Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the PI3K, Akt, and NF-kappaB-dependent pathway. J Immunol 2008; 181(12):8441-8449(SCI)

44. Yang CR, Liour SS, Dasgupta S, Yu RK. Inhibition of neuronal migration by Jones antibody is independent of 9-O-acetyl GD3. J Neurosci Res 2007; 85(7):1381-1390(SCI)

45. Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Huang PJ, Lai CC, Liu SH, Liau CS. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal 2006; 18(3):391-399(SCI)

46. Yang CR, Hsieh SL, Ho FM, Lin WW. Decoy Receptor 3 Increases Monocyte Adhesion to Endothelial Cells via NF-kB-dependent Upregulation of ICAM-1, VCAM-1 and IL-8 Expression. J Immunol 2005; 174(3):1647-1656(SCI)

47. Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 2004; 11 Suppl 1:S90-S107(SCI)

48. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 2004; 64(3):1122-1129(SCI)